Eversheds Sutherland advises Albumedix on its c£415m sale to Sartorius

Eversheds Sutherland has advised UK-based Albumedix Ltd., a biotechnology company and a leader in the field of recombinant human albumin-based solutions, on its agreed £415m sale to life sciences group, Sartorius.

Sartorius has agreed to acquire 100 percent of Albumedix Ltd. through its French listed subgroup Sartorius Stedim Biotech, from private investors.

Albumedix Ltd. provides best-in-class recombinant human albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapies.

Eversheds Sutherland provided multi-jurisdictional legal advice on the deal. The team was led by Corporate Partners Jon Cox-Brown and James Trevis and included Principal Associate Lee Harris, Associates Jake Perryman and Danielle Gibbon (corporate), Partners Peter Harper (competition), Jeff Bialos (US), Anthony Cross (Germany) and Colin Askew (tax).

Albumedix will become part of the Bioprocess Solutions Division within Sartorius, with its Nottingham, UK-based campus being established as a centre of excellence in Sartorius dedicated to bio-innovation and GMP-compliant manufacturing of critical raw materials.

The transaction is subject to regulatory approval and is expected to close before the end of the third quarter of 2022.

Jon Cox-Brown, Eversheds Sutherland, said:

“We’re thrilled to have supported Albumedix Ltd and its shareholders on this deal, which enables the company to achieve its strategic objectives and realise its ambitions for further growth. This transaction should position the company very well to meet the growing needs of its global client base.”

Charlotte Diamond, General Counsel and Company Secretary, Albumedix Ltd., said:

“Jon and the Eversheds Sutherland team were an absolute pleasure to work with. They provided high quality strategic advice and engaged seamlessly with us and our other advisers to deliver this transaction to a very tight timetable.

“This was a very important deal for Albumedix and we knew that the Eversheds Sutherland team would deliver.”